1 / 30

Medical Therapy of Prostate Symptoms (MTOPS)

Medical Therapy of Prostate Symptoms (MTOPS). Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham. Benign Prostatic Hyperplasia (BPH). Common cause of morbidity among older men Characterized by bothersome lower urinary tract symptoms (LUTS)

magar
Télécharger la présentation

Medical Therapy of Prostate Symptoms (MTOPS)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham

  2. Benign Prostatic Hyperplasia (BPH) • Common cause of morbidity among older men • Characterized by bothersome lower urinary tract symptoms (LUTS) • Men with BPH and larger prostates due to BPH are at increased risk of complications such as acute urinary retention

  3. Prevalence • Clinical Significant BPH • AUA symptom score > 7 points (moderate to severe lower urinary tract symptoms) • Depressed peak uroflow (< 15 mL/sec) • Prevalence by age group • 17% in men from 50-59 yrs of age • 27% in men from 60-69 yrs of age • 35% in men from 70-79 yrs of age

  4. MTOPS Trial Design • Randomized, double blind, 2 x 2 factorial • Two-year enrollment period • Minimum four-year follow-up period • Objective: to determine if doxazosin or finasteride, alone or in combination delayed or prevented clinical progression of BPH

  5. Inclusion Criteria • Men > 50 yrs of age • AUA symptom score of 8-35 • Peak urinary flow rate of 4-15 ml/sec • Voided volume > 15 ml

  6. Exclusion Criteria • Prior medical or surgical intervention for BPH • Supine blood pressure < 90/70 mmHg • PSA > 10 ng/ml

  7. Factorial Design

  8. Treatments • 5-areductase inhibitor Finasteride dose: 5 mg • Alpha blocker Doxazosin dose doubled weekly starting with 1 mg daily until daily dose of 8 mg reached.

  9. Follow-up Evaluations • Vital signs • AUA symptom score • Urinary flow rate • Adverse Events • DRE, serum PSA< urinalysis • Prostate volume (TRUS)

  10. Follow-up Questionnaire • AUA Symptom Score • QOL Short Form-36 (SF-36) • Sexual function questionnaire • Prostatitis Questionnaire

  11. Primary Endpoints • Primary endpoint: time to BPH progression defined as • > 4 point increase in AUA symptom score • Acute urinary retention • Renal insufficiency • Recurrent urinary tract infection • Urinary incontinence

  12. Secondary Endpoints • Changes over time • AUA symptom score • Maximal urinary flow rate • PSA level • Prostate volume • Cumulative incidence of invasive treatments for BPH

  13. Results • 3047 men randomized • Baseline characteristics • Mean age: 62.6 yrs • White: 82% • Mean AUA symptom score: 16.9 • Mean prostate volume: 36.3 ml • Mean Max urinary flow rate: 10.5 ml/min • Mean post void residual volume: 68.1 ml • Mean serum PSA: 2.4 ng/ml • Mean serum creatinine: 1.1 mg/dl

  14. Clinical Progression of BPHRate per 100 PYs

  15. Clinical Progression of BPHEvents

  16. Cumulative Incidence of Progression(N Engl J Med 2003: 349 (25): 2387-97)

  17. Rate of Progression per 100 PYs • Placebo: 4.5 BPH Progressors • Doxazosin: 2.7 BPH Progressors • Finasteride: 2.9 BPH Progressors • Combination: 1.5 BPH Progressors

  18. Invasive Therapy due to BPH

  19. Adverse Events – Sexual Function(Rate per 100 PYs) * p<0.05 compared to placebo

  20. Adverse Events – Hypotension(Rate per 100 PYs) * p<0.05 compared to placebo

  21. MTOPS Summary • Combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression more than each drug alone. • Finasteride containing regimens reduced the long-term risk of AUR and need for invasive therapy. McConnell et al, N Engl J Med 2003.

  22. Methods papers • Study Design • Bautista et al, Controlled Clinical Trials 2003 • Recruitment • Kusek et al, Controlled Clinical Trials 2002

  23. Secondary Analyses • Placebo patients – baseline factors associated with clinical progression * • Total prostate volume • PSA • Peak flow rate • Post residual volume • Age * Crawford et al, J Urol 2006

  24. Secondary Analyses • Combination therapy is better than either agent alone (finasteride, doxazosin) in decreasing the risk of clinical BPH progression in those with higher prostate volumes* Kaplan et al, J Urol 2006

  25. MPSA • MTOPS Prostatic Sample Analysis Consortium – evaluate biomarkers associated with BPH (Mullins et al, J Urol 2008).

  26. Analyses in Progress • Longitudinal analyses of sexual function • Risk of prostate cancer

  27. MTOPS Data Available • Uroflow Measurements (quarterly) • Compliance/pill counts (quarterly) • PSA measurements (semi-annually) • PE, CBC, serum chemistry, urinalysis (annually) • TRUS and Biopsy (Screening, 12 mos, end of study)

  28. MTOPS Questionnaires • AUA Symptom Questionnaire (quarterly) • Sexual Function Questionnaire (screening and end of study) • Medical Outcomes Study (MOS) – Short Form 36 (SF-36) (annually) • Prostatitis Questionnaire (annually)

  29. MTOPS Data from Diagnostic Center • PSA (ng/ml) • LH (mIU/ml) • Testosterone (ng/dl) • % Free PSA • Total PSA

  30. MTOPS Samples in NIDDK Repository

More Related